Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)

Publisher： Karger

E-ISSN： 1421-9832|214|4|310-318

ISSN： 1018-8665

Source： Dermatology, Vol.214, Iss.4, 2007-04, pp. : 310-318

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus?

By  

Dermatology, Vol. 214, Iss. 4, 2007-04 ,pp. : 275-277

Karger

Access to resources Recommend Favorite

Epidermolysis Bullosa Acquisita following Bullous Pemphigoid, Successfully Treated with the Anti-CD20 Monoclonal Antibody Rituximab

By  

Dermatology, Vol. 215, Iss. 3, 2007-09 ,pp. : 252-255

Karger

Access to resources Recommend Favorite

Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab

By  

Dermatology, Vol. 218, Iss. 3, 2008-12 ,pp. : 237-245

Karger

Access to resources Recommend Favorite

Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient

By  

Dermatology, Vol. 218, Iss. 1, 2008-10 ,pp. : 69-70

Karger

Access to resources Recommend Favorite

Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy

By  

Dermatology, Vol. 206, Iss. 4, 2003-06 ,pp. : 388-390

Karger

Access to resources Recommend Favorite